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Abstract 
Background:  Hepatitis is a common problem in Pakistan. Pakistan is the second most prevalent country 
regarding hepatitis C with a prevalence rate of 6.7%. Genotype 3 is the most commonly detected genotype in 
Pakistan. This study was conducting in Hepatitis Clinic, Medical Unit II, Jinnah Hospital Lahore and study 
duration was three months starting from 1st Dec 2018 to 28th Feb 2019. In our study we evaluate side effects of 
direct acting antivirals for hepatitis C patients by using descriptive case series. 
 Methods: Forty patients meeting the inclusion criteria were included in the study. All patients were then given 
direct anti-virals for a period of three months. Patients were called after every four weeks and observed for the 
presence of side effects like fever, fatigue, malaise, generalized weakness, myalgia, nausea and vomiting. Data 
was entered and analyzed in SPSS version ver.21.0. Frequency and percentages were calculated for demographic 
and clinical profile and side effects. Mean and Standard deviation was calculated for biochemical values at base 
line and end of therapy. Chi-square test was used to assess side effects among age, gender and duration of disease 
and paired t test for biochemical parameters with p < .05 as statistical significance. 
Results: Mean age of the patients was 39 years + 11.6. Fever was recorded in 72.5% fatigue was seen in 52.5%, 
malaise was recorded in 37.5% and generalized weakness was noticed in 37.5. Myalgia was recorded in 12.5% and 
nausea and vomiting were reported in 2.5% of patients. . (p> .05). There was a statistically significant difference 
between mean baseline and at end treatment values for AST, ALT, AP and TLC. ( P< .05).  
Conclusion: Our study concluded that along with efficacy advantage of DAA therapy, their safety profile is 
acceptable in terms of adverse drug reaction of immediate or during treatment however long term follow up is 
needed to ascertain and apprehend the safety matters linked with the utilization of DAAs. 
Key Words: Direct Acting Antivirals (DAAs), Side Effects, Chronic Hepatitis C. 
 
 
Introduction 
Hepatitis is a common problem in Pakistan.   Pakistan 
is the second most prevalent country regarding 
hepatitis C with a prevalence rate of 6.7%. Genotype 3 
is the most commonly detected genotype in Pakistan.  
Hepatitis C patients were conventionally treated with 
interferon and  ribavirin which  caused multiple  side 
effects leading to non compliance and hence failure of 
139 Journal of Rawalpindi Medical College (JRMC); 2019;23(3):138-142 
 
 
treatment .The newly developed  direct anti virals  
DAAs have opened new horizons  for the  treatment  
of hepatitis C.  Direct   anti virals have proved safe and 
efficacious.   
Sofosbuvir, a NS5B inhibitor was approved by FDA in 
2013 is the leading  direct anti viral  followed by 
daclatasvir which is a NS5A inhibitor]. According to 
ALLY 3+ trial the combination of sofosbuvir and 
daclatasvir in genotype 3 patients has proved safe and 
efficacious with minimum side effects, less drug-drug 
interactions and has safely been tried in special 
circumstances such as in patients with liver 
transplantation, renal transplantation and HIV 
patients   co-infected with hepatitis C. 
 Pakistan is developing nation with a population of 
29.5% living below poverty line, the price of direct anti 
virals is a major issue. With the availability of generics, 
a combination of sofosbuvir and daclatasvir costs as 
low as US$75 for a 12-week course that makes it 
affordable for the majority of patients in the country. 
Scarce data are available to determine the safety and 
efficacy of these low-price generic drugs. Our study is 
one such effort to establish the efficacy and safety of 
these generics in Pakistani population. 
 
Material and Methods 
After approval from ethical committee and informed 
consent forty patients of either age or gender 
presenting to the outpatient medical department of 
Medical Unit II of Jinnah Hospital with hepatitis C 
were enrolled in the study after taking informed 
consent.  All patients were then given direct anti-viral 
for a period of three months. Patients were called after 
every four weeks and observed for the presence of 
side effects like fever, fatigue, malaise, generalized 
weakness, myalgia, nausea and vomiting by 
researcher himself for controlled bias in the outpatient 
department. Data was entered and analyzed in SPSS 
version ver.21.0. Frequency and percentages were 
calculated for demographic and clinical profile and 
side effects. Mean and Standard deviation was 
calculated for biochemical values at base line and end 
of therapy. Chi-square test was used to assess side 
effects among age, gender and duration of disease and 
paired t test for biochemical parameters with p < .05 as 
statistical significance. 
 
Result 
Mean age of the patients was 39 years +11.6. Minimum 
age was 20 years and maximum age was 60 years. 
67.5% patients were less than 40 years and 32.5% of 
patients were more than 40 years in age.90% of the 
patients were males and 10% of the patients were 
females. 82.5 % of the patients were single and 17.5% 
of the patients were married. 62.5% of the patients 
belonged to rural areas while 37.5% of patients were 
from urban areas. In 75% of patients the disease was 
present for less than 6 months while in 25% of patients 
the duration of disease was more than 6 months.(Table 
1). 
Fever was recorded in 72.5% of patients with a p value 
of 0.234.Fatigue was seen in 52.5% of patients with a p 
value of 0.906.Malaise was recorded in 37.5% of 
patients with a p value of 0.161. Generalized weakness 
was noticed in 37.5% with a p value of 0.433. Myalgia 
was recorded in 12.5% with a p value of 0.161.Nausea 
and vomiting were reported in 2.5% of patients. . 
(Table 1). 
In gender cross tabulation fever was seen in 93.1% of 
males and 6.9% of females (p> .05).Fatigue was seen in 
100% of males and 0% of (p > .05)..Malaise was seen in 
86.7% of males and 13.3% of females with a p value of 
0.586.Generalized weakness was noticed in 93.3% of 
males and 6.3% of females (p > .05).. Myalgia was 
noticed in 80% of males and 20 % of females with a p 
value of 0.426. Nausea and vomiting were recorded 
in100% of males and 0% of females (p > .05). (Table 3). 
When results were recorded depending upon the 
duration of disease fever was recorded in 65.5% of 
patients with duration of infection less than 6 months 
and 34.5% of patients reported fever in whom the 
duration was more than 6 months (p < .05)..Fatigue 
was seen in 76.2% of patients with duration of disease 
less than 6 months and 23.8% of patients with duration 
of infection for more than 6 months (p > .05).. Malaise 
was recorded in 73.3% of patients with disease less 
than 6 months and 26.7% of patients with disease 
more than 6 months (p > .05)..Generalized weakness 
was recorded in 93.3% of patients with disease less 
than 6 months of duration and 6.7% of patients with 
disease more than 6 months in duration (p > .05).. 
Myalgia was reported in 60% of patients with duration 
less than 6 months of disease and in 40% of patients 
with duration more than 6 months. (p> .05). (Table 3). 
There was a statistically significant difference between 
mean baseline and at end treatment values for AST, 
ALT, AP and TLC. ( P< .05). (Table 4). 
Table no: 1 Demographic and clinical profile of 
subjects 
Variables N Percent 
Age (Mean=39 ± 11) 
< 40 years 27 67.5 
> 40 years 13 32.5 
Gender   
Male 36 90.0 
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Female 4 10.0 
Marital status   
Single 33 82.5 
Married 7 17.5 
Residential status   
Rural 25 62.5 
Urban 15 37.5 
Duration of disease (yrs) Mean=6.02 ± 5.56 
< 6 months 30 75.0 
> 6 months 10 25.0 
 
Table no: 2 Side effects experienced by subjects (multiple response frequencies) 
 
Side effect 
Responses Percent of Cases 
N Percent 
Side Effect:1 Fever 29 33.7% 72.5% 
Side Effect: 2 Fatigue 21 24.4% 52.5% 
Side Effect: 3 Malaise 15 17.4% 37.5% 
Side Effect: 4 Generalized weakness 15 17.4% 37.5% 
Side Effect: 5 Myalgia 5 5.8% 12.5% 
Side Effect: 6 Nausea Vomiting 1 1.2% 2.5% 
Total 86 100.0% 215.0% 
 
Table no:3 Side effects experienced by subjects and age, gender and duration of disease cross tabulation 
Side effects Fever Fatigue Malaise Generalized 
weakness 
Myalgia Nausea 
Vomiting 
 Freq % age Freq % age Freq % age Freq % 
age 
Fr
eq 
% age Fre
q 
% age 
Age < 40 18 62.10% 14 66.70% 12 80.00% 9 60.00
% 
2 40.00% 1 100.00
% 
> 40 11 37.90% 7 33.30% 3 20.00% 6 40.00
% 
3 60.00% 0 0.00% 
P value 0.234 0.906 0.191 0.433 0.16 0.482 
Gender 
 
Male 27 93.10% 21 100.00% 13 86.70% 14 93.30
% 
4 80.00% 1 100.00
% 
Female 2 6.90% 0 0.00% 2 13.30% 1 6.70
% 
1 20.00% 0 0.00% 
P value 0.288 0.027 0.586 0.586 0.426 0.736 
Duratio
n of 
disease 
(years) 
< 6 
months 
19 65.50% 16 76.20% 11 73.30% 14 93.30
% 
3 60.00% 1 100.00
% 
> 6 
months 
10 34.50% 5 23.80% 4 26.70% 1 6.70
% 
2 40.00% 0 0.00% 
P value 0.025 0.855 0.85 0.038 0.408 0.559 
 
Table no: 4 Base line and end point therapy comparison of liver biochemistry 
Paired Samples Statistics 
 Mean N Std. Deviation P value 
Pair 1 Bilirubin total basline 1.04 40 0.74 .042 
Bilirubin total 
Endpoint 
0.83 40 0.34 
Pair 2 PT baseline 13.00 3 0 .184 
 PT Endpoint 13.66 3 0.57 
Pair 3 ALT baseline 68.72 40 42.69 .000 
ALT Endpoint 52.65 40 30.74 
Pair 4 AST baseline 90.12 40 68 .004 
AST Endpoint 61.55 40 40.30 
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Pair 5 AP baseline 174.80 40 33.96 .012 
AP Endpoint 161.7 40 30.77 
Pair 6 TLC Baseline 5.71 40 1.02 .000 
TLC Endpoint 4.86 40 .97 
Pair 7 GT baseline 68 1 0 NA 
GT Endpoint 60 1 0 
 
Discussion 
Hepatitis C virus (HCV) infection is a major health 
problem all over the world. Approximately, 170-200 
million individuals are infected chronically worldwide 
and one fourth of these patients are at increased risk of 
developing complications such as liver cirrhosis, 
hepatocellular carcinoma and even liver failure.  
Complete eradication of the virus is the main aim in 
treatment of hepatitis C. In 2011, the first-generation 
protease inhibitors boceprevir (BOC) telaprevir (TVR) 
were approved by FDA as the direct-acting antiviral 
agents. New direct-acting antiviral agents (DAAs) 
have been developed in the past few years. Direct anti 
viral has shown increased efficacy, safety, and 
tolerability. Interferon-free oral therapies with DAAs 
are in use for patients with chronic HCV and cirrhosis 
patients.6 
A greater understanding of the hepatitis C virus 
(HCV) genome and proteins has enabled efforts to 
improve efficacy and tolerability of HCV treatment. 
Notably, this has led to the development of multiple 
direct-acting antivirals (DAAs), which are medications 
targeted at specific steps within the HCV life cycle of 
DAAs are molecules that target specific non-structural 
proteins of the virus and results in disruption of viral 
replication and infection. There are four classes of 
DAAs, which are defined by their mechanism of 
action and therapeutic target. The four classes are non-
structural proteins 3/4A (NS3/4A) protease inhibitors 
(PIs), NS5B nucleoside polymerase inhibitors (NPIs), 
NS5B non-nucleoside polymerase inhibitors (NNPIs), 
and NS5A inhibitors .7 
In a study by Gonzales 78 patients who were co 
infected with hepatitis B or HIV treated with direct 
anti viral.   21 (26.9%) patients reported adverse effects 
that were secondary to direct anti viral. The most 
common adverse effects were fatigue (47.6%), 
gastrointestinal symptoms (38.1%), anaemia (14.3%), 
and headache (14.3%). In comparison with the rest of 
the study cohort, the patients who developed adverse 
effects were more often Caucasian (33.3% vs. 10.5%, p 
= 0.017) and were more frequently treated with 
PrOD/Ribavirin (9.5% vs. 0%, p = 0.018). In terms of 
antiretroviral therapy (ART), there was a trend 
towards a more frequent use of TDF/FTC + NNRTI 
(33.3% vs. 14%, p = 0.055).8 
The overall rate of adverse effects in our study was 
26.9%, which is much lower than those reported in 
other real-world studies. The study conducted by 
Hawkins et al. on HIV/HCV coinfected patients 
revealed that 48% of patients experienced at least one 
adverse event, which is similar to the findings 
reported by Bruno et al., who found a rate of 59.7%. 
In our study most of the patients presenting in 
hepatitis clinic were of young age group less than 40 
years comprising 2/3rd of total number of patients. 
The striking feature was that mostly male gender end 
up for treatment in my study that was composed of 
90% of total patients. As mostly young ones were 
offered treatment so 82.5% were single. As the 
population of Pakistan is 62.5% based in rural area as 
also depicted by my study. Most of the patients ¾ had 
the disease for more than 6 months old.  
Dyspnoea is reported in 4%, of the patients ,which is 
lower than the rate found in our patients (8.3%).10 
Headache was a common adverse effect seen in 
controlled studies, reported approximately in 20% of 
patients on Simeprevir / Sofosbuvir; however, none of 
our patients developed headaches during their 
treatment with this regimen].9 Other clinically 
significant adverse effects that are reported in the 
literature are pruritus (14%), rash (16%), and 
photosensitivity (5%)]9,11. None of these side effects 
was reported in other study cohort. 12,13 
In our study Fever was the most evident complaint 
described by the patient in three quarters in numbers. 
Half of the patients presented with fatigue. More than 
1/3rd complaint of symptoms of malaise and general 
weakness. Just 12.5% had myalgia. Only minor 2.5% 
had symptoms of nausea and vomiting. 
 
Conclusion 
Our study concluded that along with efficacy 
advantage of DAA therapy, their safety profile is 
acceptable in terms of adverse drug reaction of 
immediate or during treatment however long term 
follow up is needed to ascertain and apprehend the 
safety matters linked with the utilization of DAAs. 
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